Myriad Genetics' third quarter was marked by the company's decision to divest its prenatal health business and continued efforts to address reimbursement pressures in hereditary cancer testing. Management highlighted volume growth in Cancer Care Continuum and mental health tests, partially offset by weakness in prenatal health. CEO Sam Raha attributed sequential improvements in average revenue per test to early progress in revenue cycle management and payer engagement initiatives, noting these actions are central to restoring profitability and operational stability.

Is now the time to buy MYGN? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our top 5 analyst questions from Myriad Genetics’s Q3 earnings call

• Bill Bonello (Craig-Hallum) asked about hereditary cancer pricing declines and whether they resulted from lower rates or increased denials. CFO Ben Wheeler clarified declines mainly stem from increased denials and revenue cycle friction rather than contract changes, and expects continued modest headwinds.
• Bill Bonello (Craig-Hallum) questioned if Myriad’s market pricing contributed to denial rates. Wheeler responded that payer denials are driven by broader specialty diagnostics spending and payer policy shifts, not Myriad's specific pricing.
• Kyle Boucher (TD Cowen) inquired about the components of fourth quarter guidance and potential factors behind expected revenue changes. Wheeler explained that the updated guidance reflects Q3 outperformance and anticipated softer prenatal volumes post-divestiture announcement.
• Kyle Boucher (TD Cowen) asked about post-divestiture strategic focus and use of proceeds. CEO Sam Raha and Wheeler indicated priorities include debt repayment, internal and external growth investments, and further enhancement of cancer care capabilities.
• Kyle Boucher (TD Cowen) requested details on profitability and growth profile excluding prenatal health. Wheeler projected over 100 basis points improvement in revenue growth and 500 basis points higher gross margin but deferred detailed guidance until planning is finalized.

Catalysts in upcoming quarters

In the coming quarters, the StockStory analyst team will monitor (1) the closing and operational transition of the prenatal health divestiture, (2) the effectiveness of Ascend-related productivity and cost initiatives, and (3) trends in reimbursement rates and test volumes within the Cancer Care Continuum and mental health segments. We will also watch for updates on reimbursement progress and early commercial traction for new products like Precise MRD.

Myriad Genetics currently trades at $6.41, up from $6.02 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Our favorite stocks right now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.